Baker Bros. Advisors’s Cabaletta Bio CABA Stock Holding History

Baker Bros. Advisors’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,331	Closed	-$227K	–	96
2024 Q1	$227K	Hold	13,331	–	–	﹤0.01%	84
2023 Q4	$303K	Sell	13,331 -1,580,669	-99%	-$26.6M	﹤0.01%	80
2023 Q3	$24.3M	Hold	1,594,000	–	–	0.14%	34
2023 Q2	$20.6M	Buy	1,594,000 +250,000	+19%	+$2.71M	0.12%	43
2023 Q1	$11.1M	Hold	1,344,000	–	–	0.06%	50
2022 Q4	$12.4M	Buy	1,344,000 +681,937	+103%	+$2.48M	0.07%	54
2022 Q3	$430K	Hold	662,063	–	–	﹤0.01%	107
2022 Q2	$702K	Hold	662,063	–	–	﹤0.01%	104
2022 Q1	$1.34M	Hold	662,063	–	–	0.01%	104
2021 Q4	$2.51M	Hold	662,063	–	–	0.01%	101
2021 Q3	$8.05M	Buy	662,063 +25,700	+4%	+$237K	0.04%	82
2021 Q2	$5.47M	Hold	636,363	–	–	0.02%	94
2021 Q1	$7.06M	Hold	636,363	–	–	0.03%	85
2020 Q4	$7.94M	Hold	636,363	–	–	0.03%	80
2020 Q3	$6.9M	Hold	636,363	–	–	0.03%	74
2020 Q2	$7.09M	Hold	636,363	–	–	0.03%	73
2020 Q1	$4.64M	Hold	636,363	–	–	0.03%	65
2019 Q4	$8.89M	Buy	+636,363	New	+$7.54M	0.05%	53

Other funds holding CABA

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Baker Bros. Advisors's CABA Position: Q2 2024 in Review

Baker Bros. Advisors sold out of Cabaletta Bio (CABA) in Q2 2024, closing a stake of 13,331 shares — an estimated $227K sold.

Baker Bros. Advisors first reported a position in CABA in Q4 2019 and held it in 18 quarters. The position peaked at $24.3M in Q3 2023. 142 funds tracked by Wall St. Rank hold CABA as of Q2 2024.

Baker Bros. Advisors reported no remaining Cabaletta Bio position as of Q2 2024 after selling out during the quarter.
Baker Bros. Advisors sold 13,331 Cabaletta Bio shares in Q2 2024, an estimated $227K.
Baker Bros. Advisors first reported a position in Cabaletta Bio in Q4 2019 and held it in 18 quarters.
Baker Bros. Advisors's Cabaletta Bio position peaked at $24.3M in Q3 2023.
142 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2024.

Based on Baker Bros. Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.